JP2011200238A5 - - Google Patents

Download PDF

Info

Publication number
JP2011200238A5
JP2011200238A5 JP2011106343A JP2011106343A JP2011200238A5 JP 2011200238 A5 JP2011200238 A5 JP 2011200238A5 JP 2011106343 A JP2011106343 A JP 2011106343A JP 2011106343 A JP2011106343 A JP 2011106343A JP 2011200238 A5 JP2011200238 A5 JP 2011200238A5
Authority
JP
Japan
Prior art keywords
cell
sirna molecule
sirna
nucleotides
overhang
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011106343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011200238A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011200238A publication Critical patent/JP2011200238A/ja
Publication of JP2011200238A5 publication Critical patent/JP2011200238A5/ja
Pending legal-status Critical Current

Links

Images

JP2011106343A 2003-07-03 2011-05-11 Ｓｙｋキナーゼ発現の阻害 Pending JP2011200238A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48429903P 2003-07-03 2003-07-03
US60/484,299 2003-07-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006517793A Division JP2007524397A (ja) 2003-07-03 2004-07-01 Ｓｙｋキナーゼ発現の阻害

Publications (2)

Publication Number Publication Date
JP2011200238A JP2011200238A (ja) 2011-10-13
JP2011200238A5 true JP2011200238A5 (cg-RX-API-DMAC7.html) 2012-08-09

Family

ID=34079054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006517793A Withdrawn JP2007524397A (ja) 2003-07-03 2004-07-01 Ｓｙｋキナーゼ発現の阻害
JP2011106343A Pending JP2011200238A (ja) 2003-07-03 2011-05-11 Ｓｙｋキナーゼ発現の阻害

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006517793A Withdrawn JP2007524397A (ja) 2003-07-03 2004-07-01 Ｓｙｋキナーゼ発現の阻害

Country Status (7)

Country Link
US (3) US7173015B2 (cg-RX-API-DMAC7.html)
EP (2) EP1692153A4 (cg-RX-API-DMAC7.html)
JP (2) JP2007524397A (cg-RX-API-DMAC7.html)
CN (2) CN100577680C (cg-RX-API-DMAC7.html)
AU (1) AU2004257167B2 (cg-RX-API-DMAC7.html)
CA (1) CA2531069A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005007623A2 (cg-RX-API-DMAC7.html)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274726B1 (en) * 2000-04-13 2009-12-23 Thomas N. Wight Therapeutic compounds and methods for modulating v3, a versican isoform
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
WO2005049838A2 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
WO2006023491A2 (en) 2004-08-16 2006-03-02 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
NZ556097A (en) 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
WO2006113743A2 (en) * 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
EP2217249A4 (en) * 2007-11-06 2011-10-12 Benaroya Res Inst INHIBITION OF VERSICAN WITH SIRNA AND OTHER MOLECULES
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
EP2350277A1 (en) * 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
KR20120091037A (ko) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 올로파타딘 조성물 및 그의 용도
WO2011100341A1 (en) * 2010-02-09 2011-08-18 Drexel University New signaling molecule involved in ultraviolet damage to skin
KR101223483B1 (ko) * 2010-09-10 2013-01-17 한국과학기술연구원 전하결합 및 생분해성 공유결합으로 동시에 연결된 고분자―ｓｉＲＮＡ 나노입자 전달체
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TW201536329A (zh) * 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2015222865B2 (en) 2014-02-28 2019-06-20 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CA2983796A1 (en) * 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
CN106715456B (zh) 2014-08-12 2023-08-29 莫纳什大学 定向淋巴的前药
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
WO2016138352A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN108289866B (zh) 2015-10-23 2025-10-28 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂和其用途
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
PL3884939T3 (pl) 2016-03-09 2024-02-26 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
JP7082130B2 (ja) 2016-10-14 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US10414727B2 (en) 2016-11-08 2019-09-17 Navitor Pharmaceuticals, Inc. Phenyl amino piperidine mTORC inhibitors and uses thereof
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
WO2018106636A1 (en) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Shmt inhibitors and uses thereof
US11730819B2 (en) 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
US10336752B2 (en) 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
EP3615019B1 (en) 2017-04-26 2025-06-04 Navitor Pharmaceuticals, Inc. Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019046491A1 (en) 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
SG11202006701TA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
MX2020007797A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
AU2019229258B2 (en) 2018-02-27 2023-09-14 Artax Biopharma Inc. Chromene derivatives as inhibitors of TCR-Nck interaction
EP4043460B1 (en) 2018-04-24 2024-06-05 Merck Patent GmbH Antiproliferation compounds and uses thereof
CA3097774A1 (en) 2018-04-24 2019-10-31 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
CN117843659A (zh) 2018-06-15 2024-04-09 詹森药业有限公司 雷帕霉素类似物和其用途
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AU2019360941B2 (en) 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
JP7644002B2 (ja) 2018-10-24 2025-03-11 ナビター ファーマシューティカルズ， インコーポレイテッド 多形化合物およびその使用
KR20250167680A (ko) 2018-11-30 2025-12-01 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CN113348021B (zh) 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4028385A4 (en) 2019-09-11 2023-11-08 Vincere Biosciences, Inc. USP30 INHIBITORS AND USES THEREOF
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
EP4051259A4 (en) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. METHOD OF TREATMENT USING A MMOC1 MODULATOR
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2020412780A1 (en) 2019-12-23 2022-07-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
AU2021217172A1 (en) 2020-02-05 2022-09-22 Monash University Lipid prodrugs of neurosteroids
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo específicos para nectina-4 y usos de estos.
JP2023546996A (ja) 2020-10-23 2023-11-08 ニンバス クロソー， インコーポレイテッド Ｃｔｐｓ１阻害剤およびその使用
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
JP2024503300A (ja) 2020-12-30 2024-01-25 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
CA3214952A1 (en) 2021-04-09 2022-10-13 Silvana Marcel LEIT DE MORADEI Cbl-b modulators and uses thereof
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2022236058A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
WO2023034870A2 (en) 2021-09-01 2023-03-09 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing dmpk expression
AU2022378630A1 (en) 2021-10-29 2024-05-09 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
JP2025504059A (ja) 2022-01-31 2025-02-06 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋデグレーダー及びその使用
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP4615455A2 (en) 2023-06-23 2025-09-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202529769A (zh) 2023-09-21 2025-08-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
AU2001249622B2 (en) * 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
EP1873259B1 (en) * 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
CA2447360A1 (en) * 2001-05-09 2002-11-14 Alk-Abello A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
WO2003067210A2 (en) * 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
AU2002362436A1 (en) * 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
US7894992B2 (en) * 2001-11-07 2011-02-22 Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004052364A1 (en) * 2002-12-06 2004-06-24 The Trustees Of Boston University METHODS FOR SUSTAINING eNOS ACTIVITY
US20040219575A1 (en) * 2002-12-26 2004-11-04 Toomas Neuman Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2004210439A1 (en) * 2003-02-05 2004-08-19 Applied Research Systems Ars Holding N.V. Mucin-like polypeptides
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
EP1692258A4 (en) * 2003-11-12 2007-03-21 Xiao Xu REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS
WO2005049838A2 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma

Similar Documents

Publication Publication Date Title
JP2011200238A5 (cg-RX-API-DMAC7.html)
EP4137161A1 (en) Method and drug for treating hurler syndrome
EP1670518B1 (en) Rna interference for the treatment of gain-of-function disorders
US7709456B2 (en) Modulation of gene expression by oligomers targeted to chromosomal DNA
EP2371835A1 (en) Inhibition of syk kinase expression
CN110484615B (zh) lncRNA在病毒性心肌炎中调控巨噬细胞极化的应用
US9045753B2 (en) siRNA molecule for inhibiting growth of melanin and application thereof
TW201336514A (zh) ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
CN108144061A (zh) microRNA-210抑制剂在制备治疗炎症性皮肤病药物上的应用
EP1725658A2 (en) Materials and methods for treatment of allergic disease
Denovan-Wright et al. Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo
JP2023505737A (ja) Ｒ１２４ｈ突然変異を備えたトランスフォーミング増殖因子ベータ誘導遺伝子の短鎖干渉ｒｎａを使用したアレル特異的サイレンシング
CN113454220B (zh) 针对人细胞间粘附分子1(icam-1)的反义药物
WO2021067613A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
CN112662671B (zh) 靶向SMN2启动子区甲基化位点nt-290所在区域的反义寡核苷酸
EP2843049B1 (en) Neuronal differentiation promoter
CN101875931B (zh) 抑制人膜铁转运蛋白辅助蛋白基因表达的siRNA重组慢病毒及应用
Scalabrin et al. The Role of Long Non-Coding
AU2021383834A9 (en) Compositions and methods for suppressing msut2
WO2025139392A1 (zh) 抑制CTGF基因表达的siRNA及其用途
JP2024510010A (ja) 癌療法
US8361985B2 (en) Short hairpin RNA for gene knockdown of NR1 subunit of the N-methyl-D-aspartate receptor and its application on pharmaceutics
CN112779252A (zh) 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
CN117866953A (zh) 靶向生长激素释放抑制激素基因的shRNA及其医药应用
Schmidt et al. 691. Efficient Downregulation of ENaC Activity by Synthetic siRNAs